Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Cipla completes transfer of Generics Business Undertaking
The facility will accommodate over 1,500 employees
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Subscribe To Our Newsletter & Stay Updated
